XML 15 R4.htm IDEA: XBRL DOCUMENT v3.19.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 12 Months Ended
Apr. 30, 2019
Apr. 30, 2018
Income Statement [Abstract]    
Oncology services revenue $ 27,067 $ 20,241
Costs and operating expenses:    
Cost of oncology services 14,265 10,553
Research and development 4,798 4,401
Sales and marketing 3,056 2,570
General and administrative 4,678 4,071
Total costs and operating expenses 26,797 21,595
Income (loss) from operations 270 (1,354)
Other expense:    
Other expense (39) (89)
Total other expense (39) (89)
Income (loss) before income tax expense 231 (1,443)
Provision for income tax 103 33
Net income (loss) $ 128 $ (1,476)
Net income (loss) per common share outstanding    
Net income (loss) per common share outstanding, basic (in usd per share) $ 0.01 $ (0.13)
Net income (loss) per common share outstanding, diluted (in usd per share) $ 0.01 $ (0.13)
Weighted average common shares outstanding    
Weighted average common shares outstanding basic (in shares) 11,340,184 10,991,105
Weighted average common shares outstanding diluted (in shares) 14,096,117 10,991,105